Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Deferred Taxes came in at $2.7 million in Q2 2026, down 72.71% YoY from $9.7 million in Q2 2025, and down 71.46% on a QoQ basis from $9.3 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 5 years of Deferred Taxes data on file, last reported at $2.7 million in Q2 2026.
- Quarterly Deferred Taxes fell 72.71% year-over-year to $2.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$9.6 million (up 89.11% YoY) and the FY2025 annual result came in at -$2.2 million, up 97.94% from the prior year.
- Deferred Taxes retreated to $2.7 million in Q2 2026, from $9.3 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $9.7 million in Q2 2025 to a low of -$107.4 million in Q4 2024.
- A 3-year average of -$9.7 million and a median of $1.6 million in 2024 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2025 — Deferred Taxes jumped 3534.36% — and 2026, when it slumped 72.71%.
- Tracing ALNY's Deferred Taxes over 3 years: stood at -$107.4 million in 2024, then jumped by 74.7% to -$27.2 million in 2025, then jumped by 109.78% to $2.7 million in 2026.
- The last three Deferred Taxes figures came in at $2.7 million (Q2 2026), $9.3 million (Q1 2026), and -$27.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.66 Mn |
| Mar 31, 2026 | 9.31 Mn |
| Dec 31, 2025 | -27.17 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 9.74 Mn |
| Mar 31, 2025 | 9.64 Mn |
| Dec 31, 2024 | -107.39 Mn |
| Sep 30, 2024 | -163,000.00 |
| Jun 30, 2024 | 340,000.00 |
| Mar 31, 2024 | 454,000.00 |
| Dec 31, 2010 | 10.88 Mn |
| Sep 30, 2010 | 83,000.00 |
| Jun 30, 2010 | -85,000.00 |
| Mar 31, 2010 | -131,000.00 |
| Dec 31, 2009 | -5.19 Mn |
| Sep 30, 2009 | 281,000.00 |